SLC5A2 and hydrops fetalis: In addition to these indicators, the benefits of SGLT-2 inhibitorsfor cardiovascular events in patients have been thoroughly confirmed in severallarge-scale clinical trials [25, 48, 66, 74], solidifying their position as afirst-line drug for treating HF.